Elena Verzoni
University of Milan
CancerUrologySurgeryOncologyRetrospective cohort studyRenal cell carcinomaImmunotherapyPazopanibMetastasectomySorafenibSunitinibEverolimusProstate cancerNephrectomyCabozantinibTargeted therapyPopulationPhases of clinical researchCancer researchMedicine
205Publications
17H-index
1,236Citations
Publications 206
Newest
Objectives The aim of our study was to collect data about of the outcome of metastatic renal cell carcinoma patients who progressed after immune checkpoint inhibitors in order to enhance data about efficacy and safety of treatment beyond immune-oncology (IO). Materials and methods A total of 162 eligible patients, progressing to IO, were enrolled from 16 Italian referral centers adhering to the Meet-Uro association. Baseline characteristics, outcome data and toxicities were retrospectively colle...
Source
#1Giuseppe ProcopioH-Index: 31
#2Alessia MennittoH-Index: 14
Last. Elena VerzoniH-Index: 17
view all 20 authors...
320Background: The multikinase inhibitor cabozantinib (Cabo) is an effective treatment option for metastatic renal cell carcinoma (mRCC). However, data on the optimal sequencing of Cabo and other a...
Source
Source
#1Marco Stellato (Università Campus Bio-Medico)H-Index: 5
#2Daniele Santini (Università Campus Bio-Medico)H-Index: 56
Last. Elena VerzoniH-Index: 17
view all 11 authors...
299Background: Bone is one of the most common site of metastasis occurring in 30% of metastatic renal cell carcinoma (mRCC) patients (pts)3,4. Skeletal metastases from mRCC are usually osteolytic a...
Source
#1Brian I. Rini (Vandy: Vanderbilt University)H-Index: 33
#2Sumanta K. Pal (City of Hope National Medical Center)H-Index: 45
Last. David F. McDermott (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 80
view all 9 authors...
278Background: Tivozanib (T) is a potent and highly selective VEGF receptor (R) tyrosine kinase inhibitor in clinical development for RCC. Axitinib is also a potent and selective VEGF-R inhibitor n...
Source
#1Guillermo VelascoH-Index: 47
Last. Laurence Albiges (Université Paris-Saclay)H-Index: 43
view all 17 authors...
BACKGROUND No available data support the potential response of relapsed recurrent renal cell carcinoma (RCC) patients treated with systemic targeted therapies (TT) after completion of adjuvant sunitinib. In this study, we aimed to assess the efficacy and tolerability of rechallenge with sunitinib and other TT in advanced setting. METHODS In this multi-institutional retrospective study, relapsed RCC patients were re-challenged with sunitinib or other systemic TT as first-line therapeutic approach...
Source
Background: The RESORT trial showed no longer relapse free survival (RFS) with sorafenib following radical metastasectomy versus observation in metastatic renal cell carcinoma patients. We present the updated 42-month follow up data. Methods: The phase II RESORT trial randomized patients (1:1) to sorafenib or observation for 52 weeks within 12 weeks from surgery. RFS, the time from randomization to disease relapse or death, was the primary endpoint. Results: Sixty-nine patients were randomized b...
Source
#1Sumanta K. Pal (City of Hope National Medical Center)H-Index: 45
#2Bernard EscudierH-Index: 89
Last. Brian I. Rini (Vandy: Vanderbilt University)H-Index: 33
view all 10 authors...
Abstract Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94;...
4 CitationsSource
#1Raffaele RattaH-Index: 10
#2Elena VerzoniH-Index: 17
Last. Giuseppe ProcopioH-Index: 31
view all 13 authors...
Source
Source
12345678910
Close Researchers